Every 8-K that TuHURA Biosciences, Inc. (HURA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HURA filings page.
TuHURA Biosciences, Inc. (HURA) borrowed an additional $650,000 on September 21, 2026, under its revolving credit facility with Parkview Holdings One LLC. The facility provides maximum loan availability of $50 million and matures on April 21, 2031; TuHURA expects to use the draw for general corporate purposes.
TuHURA said future draws depend on satisfying the facility’s conditions and that funds available may be insufficient for operations and development programs as anticipated. It also identified potential conflicts of interest arising from the lender’s affiliation with its largest stockholder.
TuHURA Biosciences, Inc. (HURA) reports a new borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility provides up to $50 million in loan availability and matures on April 21, 2031. On September 14, 2026, TuHURA drew an additional $650,000 and plans to use the proceeds for general corporate purposes, increasing its outstanding debt under this line. The company highlights that its ability to continue drawing on the facility depends on satisfying loan conditions and maintaining compliance, and notes risk that available funds could be insufficient for its operations and development programs, as well as potential conflicts of interest because the lender is affiliated with its largest stockholder.
TuHURA Biosciences, Inc. (HURA) filed an amendment to clarify details of its newly adopted 2026 Inducement Equity Incentive Plan, which the Board approved on September 10, 2026 under Nasdaq Listing Rule 5635(c)(4). The plan reserves 5,000,000 shares of common stock for equity awards to new employees as a material inducement to employment. Awards may include nonqualified stock options and other stock-based awards, but no incentive stock options. As of adoption, no equity awards have been granted, and the Board currently expects all awards to be stock options with an exercise price at or above the closing price on the grant date. Shares reserved under the plan will only become issued and outstanding if the options granted to new employees vest and are exercised.
TuHURA Biosciences, Inc. (HURA) adopted the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan on September 10, 2026, allowing equity awards to new employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The Board reserved 5,000,000 shares of common stock for issuance under this plan.
The plan, administered by the Board’s Compensation Committee or a majority of independent directors, permits nonqualified stock options, stock appreciation rights, stock, restricted stock, restricted stock units, performance shares, performance units and other stock-based awards, but does not permit incentive stock options. TuHURA also approved a related form of stock option agreement to be used with this inducement plan.
TuHURA Biosciences, Inc. (HURA) reports a new borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility, previously disclosed, has a maximum availability of $50 million and matures on April 21, 2031. On September 2, 2026, the company drew an additional $1,500,000 and states it expects to use the funds for general corporate purposes.
The company highlights forward-looking risks related to its ability to continue drawing funds under the Loan Agreement, the possibility that available funds may not be sufficient for its operations and development programs, and notes potential conflicts of interest because the lender is an affiliate of its largest stockholder.
TuHURA Biosciences, Inc. (HURA) reports an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The facility provides up to $50 million of loan availability and matures on April 21, 2031.
On August 20, 2026, the company drew an additional $650,000 and expects to use these funds for general corporate purposes. The lender is an affiliate of the company’s largest stockholder, and TuHURA highlights risks related to conditions for future drawdowns, sufficiency of available funds, and potential conflicts of interest.
TuHURA Biosciences, Inc. (HURA) reported results of its 2026 Annual Meeting and the approval of equity issued in connection with an existing credit facility. Stockholders approved issuing 1,878,287 common shares to Parkview Holdings One LLC as “Loan Fee Shares” under a previously agreed $50 million revolving credit facility, relying on private placement exemptions for an accredited investor.
Six directors were elected to serve until the 2027 annual meeting. An advisory vote approved named executive officer compensation, and stockholders indicated a preference for conducting future say-on-pay votes every three years. Cherry Bekaert LLP was ratified as independent auditor for the year ending December 31, 2026. A quorum was present, with 43,034,024 of 63,682,528 outstanding shares represented.
TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company, reported second quarter 2026 results and a corporate update focused on advancing IFx-2.0, TBS-2025 and MDSC inhibitor ADC programs. The company highlighted multiple expected milestones through 2027, including prospective orphan drug designations and key trial initiations and readouts.
TuHURA reported cash and cash equivalents of $1.0 million as of June 30, 2026, and noted access to a recently announced $50 million term credit facility from its largest shareholder, described as non-convertible and expected to extend its cash runway into 2028. The facility bears 12% annual interest, with interest paid monthly and principal due at maturity on April 21, 2031, and can be drawn as needed to fund clinical and operating expenses.
For the quarter, research and development expenses were $6.6 million versus $4.9 million a year earlier, mainly from increased clinical activity, while general and administrative expenses were $2.1 million versus $1.9 million, driven in part by non-cash stock compensation and public company costs. Net cash outflows from operating activities were $13.0 million for the six months ended June 30, 2026, compared with $10.9 million in the prior-year period, partially offset by $10.6 million of net cash from financing activities. Common shares outstanding were approximately 63.7 million at June 30, 2026.
TuHURA Biosciences, Inc. reported an additional borrowing under its existing revolving credit facility with Parkview Holdings One LLC. The Loan Agreement provides for a maximum loan availability of $50 million and matures on April 21, 2031.
On August 7, 2026, the company drew an additional $650,000 under this facility and expects to use the funds for general corporate purposes. The company notes risks related to its ability to continue drawing under the Loan Agreement and whether available funds will meet its operational and development needs.
TuHURA Biosciences, Inc. reports the creation of a direct financial obligation through an additional borrowing under its existing Loan Agreement with Parkview Holdings One LLC. The agreement provides for a revolving credit facility with a maximum availability of $50 million, maturing on April 21, 2031.
On July 28, 2026, the company drew an additional $1,500,000 under this facility and expects to use the proceeds for general corporate purposes. Management highlights risks related to its ability to meet conditions for future drawdowns, the sufficiency of available funds, and potential conflicts of interest because the lender is an affiliate of the company’s largest stockholder.
TuHURA Biosciences, Inc. has increased its borrowing under an existing revolving credit facility. The company drew an additional $1,900,000 on June 30, 2026, from a loan agreement with Parkview Holdings One LLC that provides up to $50 million in availability and matures on April 21, 2031.
The new funds are expected to be used for general corporate purposes. The filing also highlights risks that the company may not always meet conditions to draw or maintain the loan and notes that the lender is an affiliate of its largest stockholder, which could create potential conflicts of interest.
TuHURA Biosciences, Inc. has scheduled its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026. This date is more than 30 days after the prior 2025 Special Meeting held on June 23, 2025, which resets shareholder proposal and nomination deadlines.
Stockholder proposals for inclusion in the proxy materials under Rule 14a-8, as well as proxy access director nominations, other proposals, and director nominations under the Bylaws and Rule 14a-19, must be received at the company’s Tampa, Florida principal executive offices by June 27, 2026.
TuHURA Biosciences, Inc. has drawn its first funds under a previously disclosed revolving credit facility. The company received $1,700,000 on May 26, 2026 from a loan agreement with Parkview Holdings One LLC, which provides up to $50 million in borrowing capacity and matures on April 21, 2031. TuHURA plans to use this initial draw for general corporate purposes, giving it additional liquidity to support operations and development activities. The company notes risks that it may be unable to satisfy conditions for future borrowings, that available funds could still be insufficient for its needs, and that the lender is affiliated with its largest stockholder, which may create potential conflicts of interest.
TuHURA Biosciences, Inc. reported first quarter 2026 results and a corporate update centered on strengthening its balance sheet and advancing its oncology pipeline. The company highlighted a new $50 million non‑equity credit facility and recent regulatory and leadership developments.
The credit facility, signed with its largest stockholder, can be drawn as needed to fund operations, carries a 12% annual interest rate on drawn amounts, and matures on April 21, 2031, extending TuHURA’s anticipated cash runway into 2028. Cash and cash equivalents were $6.3 million as of March 31, 2026, and common shares outstanding were about 63.6 million.
For the quarter, research and development expenses were $5.2 million versus $4.6 million a year earlier, and general and administrative expenses were $2.3 million versus $2.0 million. Net cash outflows from operating activities were $4.4 million, while financing activities provided $7.2 million.
TuHURA received FDA Orphan Drug Designation for IFx‑2.0 in cutaneous melanoma and outlined multiple anticipated milestones across IFx‑2.0, its VISTA inhibitor TBS‑2025, and its bi‑specific ADC program, including a Phase 3 trial in Merkel Cell Carcinoma and a planned Phase 1b/2 trial in mutNPM1 relapsed/refractory AML.
TuHURA Biosciences, Inc. filed an amended report to update and correct its previously issued unaudited pro forma financial statements reflecting the June 30, 2025 acquisition of Kineta, Inc. The revised pro forma statement of operations for the year ended December 31, 2025 shows a combined net loss of $34.6 million, or $0.66 per share, based on 52.7 million weighted-average shares outstanding.
The filing describes the Kineta acquisition as a business combination with total estimated consideration of $16.6 million, including cash and TuHURA common stock, and recognition of in-process R&D and goodwill. It also details a June 2025 private placement of 4,759,309 common shares and an equal number of warrants that raised about $11.5 million in net proceeds.
TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, an affiliate of its largest stockholder, establishing a $50 million revolving credit facility maturing on April 21, 2031. The facility bears 12% annual interest, rising by an additional 6% during events of default, and is secured by substantially all assets of the company and its subsidiaries.
TuHURA may draw once per month, up to the greater of $1.7 million or the agreed budgeted monthly expenses, with unused capacity rolling forward. Subject to stockholder approval of related share issuances, the company expects this facility to fund operations and development programs into the first quarter of 2028. In connection with the loan, Parkview receives a low to mid‑single digit royalty on annual Net Sales of IFx‑2.0‑based products up to $450 million per year, and the agreement imposes customary covenants and change‑of‑control conversion rights.
TuHURA Biosciences, Inc. reported 2025 executive compensation decisions and released detailed pro forma results reflecting its acquisition of Kineta, Inc. and a June 2025 private placement. The compensation committee approved 2025 performance bonuses of $490,536 for CEO Dr. James Bianco and $163,393 for CFO Dan Dearborn, along with 5% cost-of-living raises, bringing their annual base salaries to $605,956 and $403,676, respectively.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025 shows a pro forma net loss attributable to common stockholders of $34,571,619, or $0.64 per share, based on 54,277,032 weighted-average shares. It incorporates TuHURA’s acquisition of Kineta, which was valued at total consideration of $16,560,163 and treated TuHURA as the accounting acquirer, and includes a June 2025 private placement of 4,759,309 shares at a combined $2.65 per share and accompanying warrant, with matching warrants exercisable at $3.3125 per share.
TuHURA Biosciences reported fourth quarter and full year 2025 results and highlighted progress across its immuno-oncology pipeline. The company is running a Phase 3 accelerated approval trial of IFx-2.0 in advanced or metastatic Merkel Cell Carcinoma and a Phase 1b/2a study in MCC of unknown primary, while advancing VISTA inhibitor TBS-2025 and an ADC program toward key 2026–2027 milestones.
Cash and cash equivalents were $3.6 million at December 31, 2025, with an additional $7.5 million received in Q1 2026 from a 2025 registered direct offering. Research and development expenses rose to $20.5 million in 2025 from $13.3 million in 2024, and general and administrative expenses increased to $7.6 million from $3.9 million, reflecting expanded operations and the Kineta acquisition. Net cash outflows from operating activities were $27.7 million in 2025, partly offset by $19.9 million of net cash inflows from financing activities. TuHURA reported approximately 52.9 million shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement because the consolidated closing bid has been below $1.00 per share for 35 consecutive business days as of January 28, 2026. The stock is not being immediately delisted, and the company has a 180-day grace period, until July 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days. If it still fails to comply, TuHURA may be eligible for a second 180-day period, potentially including measures such as a reverse stock split, and could also request a hearing to delay any suspension or delisting. The company states that the notice does not affect its business, operations, or SEC reporting, but it cautions that there is no assurance it will regain or maintain Nasdaq listing compliance.
TuHURA Biosciences, Inc. reports that a previously registered offer and sale of up to 9,321,545 shares of its common stock will now be covered by its effective Form S-3 shelf registration statement. These shares consist of 4,570,629 shares of common stock sold in a June 2, 2025 private placement and 4,750,916 shares issuable upon exercise of related warrants, all originally registered on a Form S-1 resale registration statement.
The Form S-3 shelf registration statement (File No. 333-291239), initially filed on November 3, 2025, became effective on November 22, 2025 under Section 8(a) of the Securities Act. Under Section 415(a)(6), the earlier Form S-1 resale registration is deemed terminated, and the same selling securityholders may now offer the same shares from time to time under the new shelf registration.
TuHURA Biosciences, Inc. reported that it has prepared updated unaudited pro forma financial information reflecting its recent merger activity. The company completed a two-step merger with Kineta, Inc. on June 30, 2025, following an Agreement and Plan of Merger initially signed in December 2024 and amended in May 2025. In addition, TuHURA previously closed a reverse merger with Kintara Therapeutics, Inc. on October 18, 2024.
TuHURA is now providing an unaudited pro forma condensed combined statement of operations for the nine months ended September 30, 2025 and for the year ended December 31, 2024, as if both the Kineta transaction and the Kintara reverse merger had occurred on January 1, 2024. These pro forma statements, furnished as Exhibit 99.1, are meant to help investors understand how the combined business would have looked historically after these mergers.
TuHURA Biosciences furnished an 8-K announcing that it issued a press release with financial results for the three months ended September 30, 2025, and a corporate update. The press release is attached as Exhibit 99.1 and is incorporated by reference. The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Securities Exchange Act of 1934.
TuHURA’s common stock trades on The Nasdaq Capital Market under the symbol HURA.
TuHURA Biosciences (HURA) entered into an At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to sell shares of common stock with an aggregate offering price of up to $50,000,000. Sales, if any, will occur as “at the market offerings” under Rule 415 and may begin only after the registration statement is declared effective by the SEC.
Shares will be issued off TuHURA’s Form S-3 shelf (File No. 333-291239), with a related prospectus supplement referenced. Wainwright will act as sales agent and receive a 3.0% cash commission on gross sales, and the company agreed to reimburse up to $75,000 of counsel fees. Either party can suspend or terminate the program. TuHURA currently intends to use any proceeds for working capital and general corporate purposes.
TuHURA Biosciences, Inc. filed an 8-K to provide updates on its business and operations and to refresh risk disclosures. Under Item 8.01, the company furnished Exhibit 99.1 (business updates) and Exhibit 99.2 (updated risk factors) that supplement prior 10-K and 10-Q disclosures.
Under Item 9.01, TuHURA also included Exhibit 99.3, unaudited pro forma condensed combined financial information, presented as of and for the period ended June 29, 2025 and for the year ended December 31, 2024. The filing also contains forward-looking statements language.
TuHURA Biosciences (HURA) entered a secured bridge loan facility of up to $3,000,000, with an initial $1,500,000 advance, to fund working capital. The loan bears interest at 3% per month and is due on the earlier of December 31, 2025 or 30 days after closing an equity financing with gross cash proceeds exceeding $12,000,000. A $180,000 loan fee is payable at maturity, and prepayment is allowed without penalty.
The facility is secured by a first priority perfected security interest in U.S. patents related to TuHURA’s ImmuneFx technology platform. In connection with each advance, the lender receives warrants equal to 10% of the loan amount divided by the exercise price set at the Nasdaq Official Closing price on the grant date. On the initial advance date, TuHURA issued a warrant to purchase up to 65,217 shares, immediately exercisable and expiring two years from issuance.